Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer

Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer

Aim:In our study, we aimed to determine the clinicopathological factors affecting the pathological response after neoadjuvant chemotherapy in HER2 positive breast cancer.Materials and Methods:A total of 54 HER2 expression positive cases were included in this study. Neoadjuvant chemotherapy regimen c...

Full description

Bibliographic Details
Main Authors:	Abdullah Evren YETİŞİR, Semra PAYDAŞ
Format:	Article
Language:	English
Published:	Galenos Yayincilik 2021-08-01
Series:	Namık Kemal Tıp Dergisi
Subjects:	breast cancer her2 neoadjuvant pathological complete response
Online Access:	http://namikkemalmedj.com/archives/archive-detail/article-preview/clinicopathological-factors-determining-the-pathol/48590

Similar Items

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
by: Shuling Zhou, et al.
Published: (2023-02-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2024-02-01)

Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer
by: MA Xiangmin, et al.
Published: (2022-01-01)

Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
by: Exian Mou, et al.
Published: (2024-11-01)

Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer
by: Xueying Wu, et al.
Published: (2022-01-01)

Real-world Efficacy and Safety Comparison of Neoadjuvant Treatment of HER2-positive Breast Cancer with TCbHP Versus AC-THP
by: GENG Dan, et al.
Published: (2023-08-01)

Comparison of Efficacy Between Nab-Paclitaxel or Docetaxel Combined with Carboplatin as Neoadjuvant Therapy for HER2-Positive Breast Cancer
by: Xin HAO, et al.
Published: (2024-09-01)

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2025-03-01)

Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
by: Manlu Cui, et al.
Published: (2024-10-01)

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
by: Gavin P. Dowling, et al.
Published: (2024-01-01)

Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
by: Wei Chen, et al.
Published: (2024-05-01)

Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study
by: Zhidong Lyu, et al.
Published: (2024-08-01)

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis
by: Yongxiao Wu, et al.
Published: (2024-08-01)

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
by: Xiaoyu Liu, et al.
Published: (2023-09-01)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
by: Guoshuang Shen, et al.
Published: (2021-07-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
by: In Hee Lee, et al.
Published: (2020-11-01)

Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
by: Feng Guan, et al.
Published: (2024-09-01)

A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer
by: Shan Fang, et al.
Published: (2024-02-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
by: Jung Hwan Ji, et al.
Published: (2023-01-01)

Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram
by: Hao Cui, et al.
Published: (2021-11-01)

Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: a study based on ultrasound and clinicopathological features
by: Pingjuan Ni, et al.
Published: (2025-03-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
by: Lingfeng Tang, et al.
Published: (2022-12-01)

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
by: Zhendong Shi, et al.
Published: (2024-07-01)

Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report
by: Hua-Yang Pang, et al.
Published: (2025-01-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
by: Ling-Ming Tseng, et al.
Published: (2023-12-01)

Zoledronic-acid plus neoadjuvant therapy is associated with provoking outcomes in Her2-positive breast cancer
by: Bruno de Paula, et al.
Published: (2025-01-01)

Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
by: Jiwoo Park, et al.
Published: (2023-09-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study
by: Yu Liu, et al.
Published: (2022-10-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer
by: Hikmat Abdel-Razeq, et al.
Published: (2022-08-01)

Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR
by: Ramesh Omranipour, et al.
Published: (2020-07-01)

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
by: Antolín S, et al.
Published: (2018-12-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
by: I.P.C. Buzatto, et al.

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
by: Daniel Rayson, et al.
Published: (2022-12-01)

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01)

Pathology after neoadjuvant treatment – How to assess residual disease
by: Giuseppe Viale, et al.
Published: (2022-03-01)